Science and Research

Cardiac troponin I as predictor for cardiac and other mortality in the German randomized lung cancer screening trial (LUSI)

Cardiac Troponin I (cTnI) could be used to identify individuals at elevated risk of cardiac death in lung cancer (LC) screening settings. In a population-based, randomized LC screening trial in Germany ("LUSI" study) serum cTnI was measured by high-sensitivity assay in blood samples collected at baseline, and categorized into unquantifiable/low (< 6 ng/L), intermediate (

  • Cortés-Ibáñez, F. O.
  • Johnson, T.
  • Mascalchi, M.
  • Katzke, V.
  • Delorme, S.
  • Kaaks, R.

Keywords

  • Humans
  • *Troponin I
  • Prognosis
  • Biomarkers
  • Early Detection of Cancer
  • ROC Curve
  • Predictive Value of Tests
  • *Lung Neoplasms
  • Death
  • Lung cancer screening
  • Mortality
  • Myocardial infarction
  • Risk assessment
  • Troponin
Publication details
DOI: 10.1038/s41598-024-57889-z
Journal: Sci Rep
Pages: 7197 
Number: 1
Work Type: Original
Location: TLRC
Disease Area: LC
Partner / Member: DKFZ
Access-Number: 38531926

DZL Engagements

chevron-down